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Human cytomegalovirus (HCMV), a highly prevalent
member of herpesvirus family, rarely causes disease in
immunocompetent persons. However, reactivation of
virus is of significant concern in the immunocompro-
mised individual, most notably transplant recipients and
patients with acquired immune deficiency syndrome
(AIDS) (Snydman, 2001; Levin et al., 2001). The interest
in HCMV has increased with the escalation in the num-
ber of patients undergoing immunosuppressive therapy
following organ and bone marrow transplantation, as well
as the increasing number of AIDS patients. Furthermore,
HCMV may have an important role in the development
of vascular diseases such as arteriosclerosis, restenosis
after coronary angioplasty and transplant vascular sclero-
sis (chronic rejection) (Levi, 2001; Horvath et al., 2000;
Van der Bij & Speich, 2001).
Antiviral agents currently licensed for the treatment of
HCMV infection include ganciclovir, foscarnet, cidofovir
and fomivirsen (Villarreal, 2001; Griffiths, 2002). All of
them either directly or indirectly inhibit viral polymerase,
or are able to reduce viral replication in patients who
deve-lop the clinical symptoms associated with HCMV
disease. However, toxicity associated with these drugs,
poor oral bioavailability and high relapse rates have made
their use less than optimal (Emery, 2001; Chou, 1999).
Moreover, with the advent of the virus resistance to cur-
rent drugs (Limaye, 2002), new drugs that act by a new
mechanism of action may be highly desirable for the
treatment of HCMV infection (Martinez et al., 2001;
Castro & Martinez, 2000).
In our search for new antiviral agents (Martinez et al.,
1999a, 2000a), we discovered the benzothiadiazine dioxide
(BTD)-modified acyclonucleosides, which showed a
marked activity against HCMV and varicella-zoster virus
(Martinez et al., 1997). The structure of these compounds
is unique, not only for the nature of the heterocyclic base
but also for the lack of the 5′-OH mimetic group pre-sent
in ganciclovir and other current anti-HCMV drugs, which
points to a different mechanism of action (Martinez et al.,
1999b). These factors were considered in the first opti-
mization step performed on this family of compounds lead-
ing to the BTD dibenzylderivatives as potent non-nucleo-
side HCMV inhibitors, active against some current drug-
resistant strains (Martinez et al., 1999c). Pharmacological
studies revealed that the selective biological action exerted
by the BTD derivatives against HCMV is in the early
stages of the viral replicative cycle (Martinez et al., 2000b).
As the viral target is yet unknown, a CoMFA analysis were
performed to obtain further insights into the structural
requirements for the biological activity of BTD. It suggest-
ed that the steric component is a predominant factor in the
antiviral activity of these analogues with electrostatic fac-
tors playing a smaller yet significant role. From these
results, new series of BTD derivatives were synthesized to
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The benzothiadiazine dioxide derivatives are
potent non-nucleoside human cytomegalovirus
(HCMV) inhibitors. As part of our comprehensive
structure–activity relationship (SAR) study of
these compounds, we have now proposed struc-
tural modifications on the heterocyclic moiety both
on the number and the nature of the fused hetero-
cycle and on the kind of heteroatoms pre-sent on
it. Synthesis of these new compounds (benzyl
derivatives of thiadiazines, thienothiadiazines,
benzothienothiadiazines and quinazolines) and
the antiviral evaluation against HCMV has been
performed. SAR investigation on this class of com-
pounds has defined the structural requirements
for potency and toxicity. They have revealed two
important clues: i) a fused ring to the thiadiazine
framework is necessary to maintain the anti-
HCMV action, and ii) the sulfamido moiety in the
main heterocycle is crucial to avoid cytotoxicity.
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explore the sterics’ requirement for their biological activity
(Martinez et al., 2000c, 2003) (Figure 1).
In the present work, new structural modifications have
been proposed to improve the knowledge about the structur-
al requirements for the anti-HCMV activity of BTD deriv-
atives. The benzothiadiazine main framework is now modi-
fied. Elimination and modifications of the number and the
nature of the fused heterocyclic system are here described. As
thiophene is the classical bioisoster analogue of benzene, we
here considered thienothiadiazine system a good starting
point. We also studied analogues in which the fused hetero-
cycle to the thiadiazine ring has been elimina-ted. The three
fused system as the benzothienothiadiazine was assayed as
potential HCMV inhibitors. On the other hand, to asses the
influence of the sulfamido group in the antiviral activity of
these compounds, substitution of this group by urea or
thiourea moieties is also described.
Material and methods
Chemistry
Melting points were determined with a Reichert-Jung
Thermovar apparatus and are uncorrected. Flash column
chromatography was carried out at medium pressure using
silica gel (E Merck, Grade 60, particle size 0.040–0.063 mm,
230–240 mesh ASTM) and preparative centrifugal circular
thin layer chromatography (CCTLC) on a circular plate
coated with a 1 mm layer of Kieselgel 60 PF254, Merk, by
using a Chromatotron® with the indicated solvent as eluent.
Compounds were detected with UV light (254 nm). 1H
NMR spectra were obtained on Varian XL-300 and
Gemini-200 spectrometers working at 300 and 200 MHz
respectively. Typical spectral parameters were: spectral width
10 ppm, pulse width 9 µs (57°), data size 32 K. 13C NMR
experiments were carried out on the Varian Gemini-200
spectrometer operating at 50 MHz. The acquisition param-
eters were: spectral width 16 kHz, acquisition time 0.99 s,
pulse width 9 µs (57°), data size 32 K. Chemical shifts are
reported in d values (ppm) relative to internal Me4Si and J
values are reported in Hertz. The analytical department at
C.N.Q.O. (CSIC) performed elemental analyses and the
results obtained were within ±0.4% of the theoretical values.
1-[(4-Chlorophenyl)methyl]-thieno[3,2-c][1,2,6]-thiadi-
azin-4(3H)-one 2,2-dioxide (3)
To a solution of thienothiadiazine dioxide 1 (Martinez et al.,
2000a) (0.30 g, 1.4 mmol) in aqueous saturated solution of
sodium bicarbonate (20 ml), 4-chlorophenylmethyl chloride
(0.35 g, 2.1 mmol) was added. The reaction mixture was
refluxed for 24 h. After cooling to room temperature, the
aqueous phase was washed with CH2Cl2 (1x10 ml). The
aqueous phase was cooled at –4°C and the pro-duct was iso-
lated by filtration of aqueous phase. Purification: recrystal-
lization from toluene/MeOH, yield 0.28 g (60 %) as a solid;
mp 325–327°C.
δH (DMSO-d6) 4.89 (2H, s, NCH2), 6.58 (1H, d, JH6H7
5.3 Hz, H-7), 7.40–7.46 (4H, m, Ar-H), 7.57 (1H, d, H-6);
δC (DMSO-d6) 47.81 (NCH2), 114.85 (C-4a), 117.17 (C-
7), 128.28, 129.16, 131.60, 137.24 (Ar-C), 129.55 (C-6),




To a solution of thienothiadiazine dioxide 1 (Martinez et al.,
2000a) (0.40 g, 2.0 mmol) in aqueous saturated solution of
sodium bicarbonate (20 ml), 3,4-dichlorophenylmethyl
chloride (0.58 g, 2.9 mmol) was added. The reaction mixture
was refluxed for 24 h. After cooling to room temperature,
the aqueous phase was washed with CH2CI2 (1x10 ml).
The aqueous phase was cooled at –4°C and the pro-duct
was isolated by filtration of aqueous phase. Purification:
recrystallization from toluene/MeOH, yield 0.40 g (56 %) as
a solid; mp 246–248°C.
δH (DMSO-d6) 4.89 (2H, s, NCH2), 6.69 (1H, d, JH6H7
5.1 Hz, H-7), 7.39–7.57 (3H, m, Ar-H), 7.55 (1H, d, H-6);
δC (DMSO-d6) 47.40 (NCH2), 114.93 (C-4a), 117.00 (C-
7), 127.59, 129.15, 129.53, 129.60, 130.84, 139.52 (Ar-C),
130.45 (C-6), 144.58 (C-7a), 162.47 (C-4). Anal. for
C12H8N2O3S2Cl2 (C, H, N, S).
1-[(4-Chlorophenyl)methyl]-3-benzyl-thieno[3,2-
c][1,2,6]-thiadiazin-4-one 2,2-dioxide (5)
To an equimolecular suspension of sodium hydride in DMF
(25 ml) were added thienothiadiazine 3 (0.07 g, 0.2 mmol)
and benzyl bromide (0.05 g, 0.3 mmol). The reaction 



























Figure 1. Benzothiadiazine dioxide derivatives
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mixture was refluxed for 10 h. The solvent was evaporated
under reduced pressure. The residue was dissolved in water
and the aqueous phase was extracted with CH2Cl2 (2x10
ml). The organic phase was dried over sodium sulphate and
the solvent evaporated under reduced pressure. The residue
was chromatographed on thin layer chromatography, using
CH2Cl2:hexane (1:1) as eluent. Compound 5 was obtained
(0.006 g, 7%) as a solid; mp 85–86°C.
δH (CDCl3) 4.81 (2H, s, N1CH2), 4.97 (2H, s, N3CH2),
6.70 (1H, d, JH6H7 Hz, H-7), 6.97–7.36 (9H, m, Ar-H),
7.57 (1H, d, H-6); δC (CDCl3) 46.11 (N3CH2), 54.52
(N1CH2), 119.91 (C-7), 120.85 (C-4a), 128.15, 128.59,
128.96, 129.07, 129.28, 132.20, 134.60, 135.57 (Ar-C),
134.22 (C-6), 142.67 (C-7a), 157.74 (C-4). Anal. for
C19H15N2O3S2Cl: (C, H, N, S).
1-[(3,4-Dichlorophenyl)methyl]-3-benzyl-thieno[3,2-
c][1,2,6]-thiadiazin-4-one 2,2-dioxide (6)
To an equimolecular suspension of sodium hydride in
DMF (25 ml) were added thienothiadiazine 4 (0.10 g, 0.2
mmol) and benzyl bromide (0.05 g, 0.3 mmol). The reac-
tion mixture was refluxed for 5 h. The solvent was evapo-
rated under reduced pressure. The residue was dissolved in
water and the aqueous phase was extracted with CH2Cl2
(2x10 ml). The organic phase was dried over sodium sul-
phate and the solvent evaporated under reduced pressure.
The residue was chromatographed on thin layer chro-
matography, using CH2Cl2:hexane (1:1) as eluent.
Compound 6 was obtained (0.02 g, 18%) as a solid; mp
102–104°C.
δH (CDCl3) 4.78 (2H, s, N1CH2), 4.98 (2H, s, N3CH2),
6.70 (1H, d, JH6H7 5.2 Hz, H-7), 7.18–7.36 (8H, m, Ar-H),
7.60 (1H, d, H-6); δC (CDCl3) 46.20 (N3CH2), 53.83
(N1CH2), 119.60 (C-7), 120.65 (C-4a), 127.00, 128.19,
128.62, 128.87, 129.77, 130.95, 132.96, 133.09, 134.17,
135.52 (Ar-C), 134.48 (C-6), 142.61 (C-7a), 157.63 (C-
4). Anal. for C19H14N2O3S2Cl2: (C, H, N, S).
1-[(4-Chlorophenyl)methyl]-benzothieno[3,2-
a][1,2,6]-thiadiazin-4(3H)-one 2,2-dioxide (7) and
1,3-bis[(4-chlorophenyl)methyl]-benzothieno[3,2-
a][1,2,6]-thiadiazin-4-one 2,2-dioxide (8)
To a solution of benzothienothiadiazine dioxide 2 (Martinez
et al., 2000d) (0.30 g, 1.1 mmol) in aqueous sa-turated solu-
tion of sodium bicarbonate (20 ml), 4-chlorophenylmethyl
chloride (0.28 g, 1.7 mmol) was added. The reaction mixture
was refluxed for 6 h. After cooling to room temperature, the
aqueous phase was extracted with CH2Cl2 (4×10 ml). The
organic phase was dried over sodium sulphate and the solvent
evaporated under reduced pressure. The residue was chro-
matographed on silica gel column, using CH2Cl2:MeOH
(50:1) as eluent. From the first fraction was isolated deriva-
tive 8: yield 0.01 g (2%) as a solid; mp 158–160°C.
δH (CDCl3) 4.79 (2H, s, N3CH2), 4.94 (2H, s, N1CH2),
6.81–7.34 (8H, m, Ar-H), 7.51 (1H, t, JH8H7 7.0 Hz, H-7),
7.58 (1H, t, H-8), 7.82 (1H, d, JH8H9 8.0 Hz, H-9), 7.93
(1H, d, JH7H6 7.3 Hz, H-6); δC (CDCl3) 45.62 (N3CH2),
56.09 (N1CH2), 122.99 (C-9), 124.15 (C-6), 125.40 (C-
4a), 126.00 (C-7), 128.78 (C-8), 128.83, 129.91, 130.66,
130.92, 133.81, 134.25, 135.08 (Ar-C), 131.57 (C-5a),
137.15 (C-9b), 140.35 (C-9a), 158.47 (C-4). Anal. for
C23H16N2O3S2Cl2: (C, H, N, S).
From the second fraction, derivative 7 was isolated: yield
0.13g (30%) as a white solid; mp 230–232°C.
δH (CDCl3) 5.02 (2H, s, N1CH2), 7.25–7.30 (5H, m,
Ar-H, H-7), 7.37 (1H, t, JH7H8 7.1 Hz, H-8), 7.68 (1H, d,
JH8H9 8.0 Hz, H-9), 7.87 (1H, d, JH7H6 7.6 Hz, H-6); δC
(CDCl3) 51.94 (N1CH2), 122.88 (C-9), 123.75 (C-6),
122.13 (C-4a), 124.44 (C-7), 126.49 (C-8), 128.10,
128.94, 131.53, 137.00 (Ar-C), 132.46 (C-5a), 139.10 (C-
9b), 137.00 (C-9a), 164.32 (C-4). Anal. for
C16H11N2O3S2Cl: (C, H, N, S).
1-[(4-Chlorophenyl)methyl]-3-benzyl-benzoth-
ieno[3,2-a][1,2,6]-thiadiazin-4-one 2,2-dioxide (9)
To an equimolecular suspension of sodium hydride in
DMF (25 ml) were added benzotienothiadiazine 7 (0.08 g,
0.2 mmol) and benzyl bromide (0.05 g, 0.3 mmol). The
reaction mixture was refluxed for 6 h. The solvent was
evaporated under reduced pressure. The residue was dis-
solved in water and the aqueous phase was extracted with
CH2Cl2 (2×10 ml). The organic phase was dried over sodi-
um sulphate and the solvent evaporated under reduced
pressure. The residue was chromatographed on thin layer
chromatography, using CH2Cl2:hexane (1:1) as eluent.
Compound 9 was obtained (0.01 g, 14%) as a solid; mp
167–168°C.
δH (CDCl3) 4.86 (2H, s, N3-CH2), 4.93 (2H, s, N1-
CH2), 6.82–7.42 (9H, m, Ar-H), 7.49 (1H, t, H-7), 7.57
(1H, t, JH7H8 8.0 Hz, H-8), 7.81 (1H, d, JH8H9 8.0 Hz,
H-9), 7.92 (1H, d, JH7H6 7.5 Hz, H-6); δC (CDCl3)
46.51 (N3CH2), 56.05 (N1CH2), 122.91 (C-9), 124.12 (C-
6), 125.48 (C-4a), 125.91 (C-7), 128.66 (C-8), 128.60,
128.79, 129.23, 129.92, 131.12, 134.93 (Ar-C), 131.67 (C-
5a), 137.17 (C-9b), 140.30 (C-9a), 158.53 (C-4). Anal. for





To an equimolecular suspension of sodium hydride in
DMF (25 ml) were added the thiadiazine dioxide 10
(Goya & Stud, 1978; Su et al., 1981) (0.10 g, 0.6 mmol)
and 4-chlorophenylmethyl chloride (0.27 g, 1.6 mmol).
The reaction mixture was refluxed for 48 h. The solvent
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was evaporated under reduced pressure. The residue was
dissolved in water and the aqueous phase was extracted
with CH2Cl2 (4×10 ml). The organic phase was dried over
sodium sulphate and the solvent evaporated under reduced
pressure. The residue was chromatographed on circular
thin layer chromatography, using CH2Cl2:hexane (2:1) as
eluent. From the first fraction, derivative 11 was isolated:
yield 0.02g (9%) as a white solid; mp 111–113°C.
δH (CDCl3) 4.84 (2H, s, N6CH2), 5.26 (2H, s, OCH2),
5.51 (1H, d, JH5H4 8.0 Hz, H-4), 6.94 (1H, d, H-5),
7.29–7.36 (8H, m, Ar-H); δC (CDCl3) 51.29 (N6CH2),
69.13 (OCH2), 92.65 (C-4), 146.03 (C-5), 128.90, 129.36,
129.92, 130.10, 132.72, 132.78, 134.79, 134.90 (Ar-C),
167.51 (C-3). Anal. for C17H14N2O3SCl2: (C, H, N, S).
From the second fraction, derivative 12 was isolated:
yield 0.01g (4%) as syrup.
δH (CDCl3) 4.77 (2H, s, N6CH2), 4.94 (2H, s, N2CH2),
5.67 (1H, d, JH5H4 8.3 Hz, H-4), 6.80 (1H, d, H-5),
7.13–7.30 (8H, m, Ar-H); δC (CDCl3) 44.77 (N2CH2),
52.36 (N6CH2), 104.82 (C-4), 139.68 (C-5), 128.73,
129.39, 129.44, 130.22, 132.06, 133.96, 134.06 (Ar-C),
161.71 (C-3). Anal. for C17H14N2O3SCl2: (C, H, N, S).
General procedure for the N1-alkylation of
3-benzyl quinazoline derivatives
To a suspension of sodium bicarbonate in excess in DMF
(25 ml), N3-benzyl quinazolinedione 13 (Singh & Bhandari,
1976) or thioxoquinazolinone 14 (Wagner & Rothe, 1969)
and the corresponding alkylant agent (1.5 mmol) was added.
The reaction mixture was refluxed for 12 h. The solvent was
evaporated under reduced pressure. The residue was dis-
solved in water and the aqueous phase was extracted with
CH2Cl2 (2×10 ml). The organic phase was dried over sodi-
um sulphate and the solvent evaporated under reduced pres-
sure. The residue was chromatographed on circular thin layer
chromatography, using CH2Cl2:hexane (2:1) as eluent.
1-[(4-Chlorophenyl)methyl]-3-benzyl-quinazolin-2,
4-dione (15)
Reagents: quinazolinedione 13 (0.11 g, 0.4 mmol), 4-
chlorophenylmethyl chloride (0.11 g, 0.6 mmol). Yield:
0.07 g (40%) as a white solid: mp 148–150°C.
δH (CDCl3) 5.32 ( 2H, s, N1-CH2), 5.32 (2H, s, N3-
CH2), 7.03 (1H, d, JH7H8 8.5, H-8), 7.16–7.55 (10H,
m, Ar-H, H-6), 7.50 (1H, t, JH6H7 7.3, H-7), 8.24 (1H,
d, JH6H5 7.9, H-5); δC (CDCl3) 45.17 (N3-CH2), 46.81
(N1-CH2), 114.09 (C-8), 115.82 (C-4a), 123.23 (C-6),
127.66, 127.88, 128.45, 128.98, 129.14, 133.53, 134.18,
136.91 (Ar-C), 129.28 (C-5), 135.12 (C-7), 139.71 (C-
8a), 151.37 (C-2), 161.61 (C-4). Anal. for
C22H17N2O2Cl: (C, H, N).
1-[(3,4-Dichlorophenyl)methyl]-3-benzyl-quinazolin-
2,4-dione (16)
Reagents: quinazolinedione 13 (0.15 g, 0.6 mmol), 3,4-
dichlorophenylmethyl chloride (0.17 g, 0.9 mmol). Yield:
0.05 g (21%) as a white solid: mp 85–86°C.
δH (CDCl3) 5.21 (2H, s, N1-CH2), 5.24 (2H, s, N3-
CH2), 6.98 (1H, d, JH7H8 8.1, H-8), 6.92–7.50 (10H, m,
Ar-H, H-6, H-7), 8.17 (1H, d, JH6H5 7.9, H-5); δC
(CDCl3) 45.14 (N3-CH2), 46.34 (N1-CH2), 113.83 (C-8),
115.74 (C-4a), 123.38 (C-6), 125.81, 127.68, 128.45,
128.91, 129.35, 131.82, 133.12, 135.94, 136.74 (Ar-C),
130.90 (C-5), 135.23 (C-7), 139.43 (C-8a), 151.27 (C-2),
161.48 (C-4). Anal. for C22H16N2O2Cl2: (C, H, N).
1-[(4-Nitrophenyl)methyl]-3-benzyl-quinazolin-2,4-
dione (17)
Reagents: quinazolinedione 13 (0.15 g, 0.6 mmol), 4-nitro-
phenylmethyl bromide (0.19 g, 0.9 mmol). Yield: 0.07 g
(29%) as a yellow solid: mp 153–154°C.
δH (CDCl3) 5.27 (2H, s, N1-CH2), 5.39 (2H, s, N3-
CH2), 6.91 (1H, d, JH7H8 8.5, H-8), 7.15–8.15 (11H, m,
Ar-H, H-6, H-7), 8.21 (1H, d, JH6H5 7.9, H-5); δC
(CDCl3) 45.21 (N3-CH2), 46.88 (N1-CH2), 113.71 (C-8),
115.89 (C-4a), 123.50 (C-6), 124.20, 127.27, 127.72,
128.47, 128.95, 136.77, 143.16, 147.56 (Ar-C), 129.52 (C-
5), 135.24 (C-7), 139.46 (C-8a), 151.33 (C-2), 161.42 (C-
4). Anal. for C22H17N3O4: (C, H, N).
1-{[(4-Trifluoromethyl)phenyl]methyl}-3-benzyl-
quinazolin-2,4-dione (18)
Reagents: quinazolinedione 13 (0.15 g, 0.6 mmol), 4-tri-
fluoromethylphenylmethyl chloride (0.17 g, 0.9 mmol).
Yield: 0.09 g (38%) as a white solid: mp 160–161°C.
δH (CDCl3) 5.34 (2H, s, N1-CH2), 5.41 (2H, s, N3-
CH2), 7.01 (1H, d, JH7H8 8.4, H-8), 7.19–7.59 (11H, m,
Ar-H, H-6, H-7), 8.26 (1H, d, JH6H5 7.9, H-5); δC
(CDCl3) 45.12 (N3-CH2), 46.91 (N1-CH2), 113.91 (C-8),
115.75 (C-4a), 123.26 (C-6), 125.82 (CF3), 125.88,
126.67, 127.62, 128.40, 128.90, 136.81, 139.77 (Ar-C),
129.26 (C-5), 135.13 (C-7), 139.57 (C-8a), 151.30 (C-2),
161.49 (C-4). Anal. for C23H17N2O2F3: (C, H, N).
1-[(4-Chlorophenyl)methyl]-3-benzyl-2-thioxo-quina-
zolin-4-one (19)
Reagents: thioxoquinazolinone 14 (0.15 g, 0.5 mmol), 4-
chlorophenylmethyl chloride (0.13 g, 0.7 mmol). Yield:
0.09 g (48%) as a white solid: mp 96–98°C.
δH (CDCl3) 4.35 (2H, s, N1-CH2), 5.25 (2H, s, N3-
CH2), 7.49 (1H, d, JH7H8 8.1, H-8), 7.14–7.32 (10H, m,
Ar-H, H-6), 7.61 (1H, t, JH6H7 7.0, H-7), 8.15 (1H, d,
JH6H5 8.0, H-5); δC (CDCl3) 35.84 (N1-CH2), 47.25
(N3-CH2), 119.36 (C-4a), 125.87 (C-8), 125.97 (C-6),
127.21 (C-5), 127.45, 127.65, 128.53, 128.62, 130.62,
A Martinez et al.
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133.30, 135.08, 135.35 (Ar-C), 134.49 (C-7), 147.23 (C-
8a), 155.55 (C-2), 161.87 (C-4). Anal. for C22H17N2OSCl:
(C, H, N, S).
1-[(3,4-Dichlorophenyl)methyl]-3-benzyl-2-thioxo-
quinazolin-4-one (20)
Reagents: thioxoquinazolinone 14 (0.15 g, 0.5 mmol), 3,4-
dichlorophenylmethyl chloride (0.13 g, 0.7 mmol). Yield:
0.08 g (36%) as a white solid: mp 129–131°C.
δH (CDCl3) 4.41 (2H, s, N1-CH2), 5.35 (2H, s, N3-
CH2), 7.58 (1H, d, JH7H8 8.0, H-8), 7.23–7.35 (8H, m,
Ar-H), 7.40 (1H, t, JH6H7 7.1, H-6), 7.71 (1H, t, H-7),
8.24 (1H, d, JH6H5 8.0, H-5); δC (CDCl3) 35.32 (N1-
CH2), 47.31 (N3-CH2), 119.46 (C-4a), 125.96 (C-8),
126.02 (C-6), 127.30 (C-5), 127.46, 127.74, 128.60,
130.38, 131.29, 131.56, 132.40, 135.35, 137.14 (Ar-C),
134.58 (C-7), 147.22 (C-8a), 155.55 (C-2), 161.87 (C-4).
Anal. for C22H16N2OSCl2: (C, H, N, S).
1-[(4-Nitrophenyl)methyl]-3-benzyl-2-thioxo-quina-
zolin-4-one (21)
Reagents: thioxoquinazolinone 14 (0.15 g, 0.5 mmol), 4-
nitrophenylmethyl bromide (0.16 g, 0.7 mmol). Yield: 0.01
g (7%) as a yellow solid: mp 145–148°C.
δH (CDCl3) 4.48 (2H, s, N1-CH2), 5.29 (2H, s, N3-
CH2), 7.35 (1H, t, JH7H6 7.0, H-6), 7.48–8.09 (11H, m,
Ar-H, H-8, H-7), 8.17 (1H, d, JH6H5 7.9, H-5); δC
(CDCl3) 35.63 (N1-CH2), 47.37 (N3-CH2), 119.53 (C-
4a), 125.95 (C-8), 126.16 (C-6), 127.40 (C-5), 123.68,
127.49, 127.80, 128.64, 134.63, 135.37, 144.73 (Ar-C),
130.06 (C-7), 147.18 (C-8a), 155.28 (C-2), 161.84 (C-4).
Anal. for C22H17N3O3S: (C, H, N, S).
1-{[(4-Trifluoromethyl)phenyl]methyl}-3-benzyl-2-
thioxo-quinazolin-4-one (22)
Reagents: thioxoquinazolinone 14 (0.15 g, 0.5 mmol), 4-
trifluoromethylphenylmethyl chloride (0.14 g, 0.7 mmol).
Yield: 0.10 g (46%) as a white solid: mp 100–102°C.
δH (CDCl3) 4.74 (2H, s, N1-CH2), 5.30 (2H, s, N3-
CH2), 7.19–7.55 (11H, m, Ar-H, H-6, H-8), 7.60 (1H, t,
JH6H7 7.0, H-7), 8.19 (1H, d, JH6H5 7.9, H-5); δC
(CDCl3) 35.88 (N1-CH2), 47.29 (N3-CH2), 119.41 (C-
4a), 125.45 (C-8), 125.99 (CF3), 126.01 (C-6), 127.72 (C-
5), 125.40, 127.28, 127.46, 128.58, 129.59, 135.34, 140.94
(Ar-C), 134.57 (C-7), 147.21 (C-8a), 156.65 (C-2),
161.91 (C-4). Anal. for C23H17N2OSF3: (C, H, N, S).
Virology
Cells
Human embryonic lung MRC-5 fibroblasts were propa-
gated in Hepes modified medium 199 supplemented with
10% inactivated fetal calf serum and 1% l-glutamine.
Viruses
AD-169 strain of HCMV was used. Virus stocks consisted
of cell-free virus obtained from the supernatant of infected
cell cultures that have been sonicated and clarified by low
speed centrifugation. The virus stocks were stored at –80°C.
Antiviral assays
Confluent MRC-5 cells grown in 24-well plates were
infected with the AD-169 strain at 50 (CMV) plaque
forming units (PFU/well). After a 1.5 h incubation period,
residual virus was removed and the infected cells were fur-
ther incubated with Hepes modified medium 199 supple-
mented with 2% inactivated FCS and 1% l-glutamine con-
taining serial dilutions of the test compounds (in dupli-
cate). After 8 days of incubation at 37°C in 5% CO2 atmos-
phere, the cells were stained with 0.2% crystal violet in
ethanol:water (20:80). PFU (virus input: 50 PFU/well) was
monitored microscopically. The antiviral activity is
expressed as IC50 that represents the compound concentra-
tion required to reduce the virus plaque formation by 50%.
IC50s were estimated from graphic plots of the number of
plaques (percentage of control) as a function of the concen-
tration of the test compounds.
Cytotoxicity assays
Cytotoxicity measurements were based on the inhibition of
MRC-5 cell growth. MRC-5 fibroblasts were seeded at a
rate of 5×103 cells/well microtitre plates and were allowed
to proliferate for 24 h. Different concentrations of the test
compounds were then added (in duplicate), and after 8 days
of incubation at 37°C in 5% CO2 atmosphere, the cell
number was determined with a coulter counter.
Cytotoxicity is expressed as CC50, which represents the
compound concentration required to reduce cell growth by
50%.
Results
The thienotiadiazine 1 (Martinez et al., 2000a) and ben-
zothienothiadiazine 2 (Martinez et al., 2000d) dioxide rings
were prepared following a synthetic strategy that involves
the cyclocondensation of the corresponding functionalised
heterocycles with sulphamoyl chloride as the key step.
Benzyl thienothiadiazine derivatives (3–4) were
obtained by reaction of thienothiadiazine 1 with the appro-
priate benzyl chloride derivatives in aqueous bicarbonate.
Disubstituted compounds (5–6) could be obtained by reac-
tion of the corresponding monosubstituted derivatives with
benzyl bromide in a polar non-protic solvent such as
dimethylformamide (DMF), using sodium hydride (NaH)
as base (Figure 2). The 4-chlorophenylmethyl and 3,4-
dichlorophenylmethyl substituents attached to the N1, and
benzyl substituent attached to the N3 of these heterocycles,
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were chosen because of their good anti-HCMV activity
previously shown in the BTD series.
In the same way, we prepared the benzothienothiadi-
azine derivatives (7–9). In this case, a mixture of monoalkyl
and dialkyl compounds was obtained when we alkylated 2
with 4-chlorobenzylchloride in aqueous bicarbonate. This
could be separated by silica gel column chromatography
(Figure 3).
The 1,2,6-thiadiazine 1,1-dioxide 10, a SO2-uracil
related derivative in which the fused ring is eliminated, was
prepared in four steps according to a procedure previously
described (Goya & Stud, 1978; Su et al., 1981).
Disubstituted compounds (11–12) were obtained by alkyla-
tion with 4-chlorophenylmethyl chloride in DMF and
NaH (Figure 4).
For the preparation of 1H,3H-quinazoline-2,4-diones
and 1H,3H-quinazoline-2-thio-4-one derivatives, an unam-
biguous synthetic pathway was planned to obtain N3-benzyl
derivatives. We choose as starting material 13 and 14
unequivocally prepared from methylanthranilate and ben-
zylisocyanate or benzylisothiocyanate, respectively
(Wagner & Rothe 1969; Singh & Bhandari, 1976).
Alkylation of compounds 13 and 14 in basic medium
(DMF, NaHCO3) afforded the required N,N′-disubstitut-
ed derivatives 15–22 (Figure 5).
The structure of all new compounds was elucidated from
their analytical and spectroscopic data (1H and 13C NMR),
which are collected in the experimental section. Unequivocal
assignment of all chemical shifts (1H and 13C NMR) was
done using bidimensional experiments such as COSY or
HMQC for one bond correlation. The site of alkylation was
determined from the chemical shifts of benzylic CH2 signals
and by means of n.O.e. experiments and sequences of
HMBC for long distance proton/carbon correlation.
Discussion
The new disubstituted derivatives here described, were
evaluated for their antiviral activity against the laboratory
strain of HCMV AD-169. Antiviral activity was deter-
mined by plaque reduction assay in confluent human
embryonic lung MRC-5 fibroblast. Cytotoxicity measure-
ments were based on the inhibition of cell growth. The
results are presented in Table 1.
The thieno and benzothienothiadiazine derivatives (5,
6, 8 and 9), maintain antiviral activity against HCMV,


























Reagents: (i) RPhCH2Cl/NaHCO3/∆; (ii) BrBn/DMF/NaH/∆.

































Reagents: (i) 4-ClPhCH2Cl/NaHCO3/∆; (ii) BrBn/DMF/NaH/∆.
Figure 3. Synthesis of benzothienothiadiazine dioxide derivatives
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being some of them equipotent with the standard reference
ganciclovir. The IC50 values were in the same order than
those previously obtained for their BTD analogues
(Martinez et al., 2000b) collected in Table 1, but now the
CC50 value is slightly lower showing compounds a little more
cytotoxic. Otherwise, in the 1,2,6-thiadiazine 1,1-dioxide
derivatives (11,12) we observed increase both in the IC50
value and in cytotoxicity. From these results, we can conclude
that the HCMV receptor for the BTD, tolerates modifica-
tions on the nature and the number of the fused heterocycles,
but does not tolerate the lack of it.
When the anti-HCMV activity of quinazoline derivatives
(15–22) were measured, we observed a high cytotoxic effect
for all the compounds at the concentrations assayed (CC50<5
µM) discarding this new series of compounds from any fur-
ther development. This fact revealed that the sulfamido moi-
ety is a key structural feature for cytotoxicity modulation.
The lack of planarity present in the thiadiazine ring (Elguero
et al., 1990) regarding their oxo or thioxo analogues here
described could provide a different binding mode to the cell
and viral targets, respectively.
As a result of structural modifications carried out in the
BTD main heterocycle, some structural requirements have
been discovered that could help to modulate potency/toxici-
ty of these derivatives. Two important structure-activity rela-
tionships have been delineated: i) a fused ring to the thiadi-
azine framework is necessary to maintain the anti-HCMV,
action and ii) the sulfamido moiety in the main heterocycle
is crucial to avoid cytotoxicity. Further research is in progress
to determine the crucial HCMV receptor in which the BTD
family of inhibitors exert its specific antiviral action.
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Figure 5. Synthesis of quinazoline derivatives
Reagents: (i) Toluene, 10°C; (ii) NaOH 6N; (iii) RPhCH2Cl/NaHCO3/∆.
Table 1. Anti-HCMV (strain AD-169) activity of thia-
diazine dibenzyl derivatives








di4Cl-BTD § 3.3 >56
4Cl-BTD § 3.6 >60
*50% inhibitory concentration, or concentration required to reduce
virus plaque formation by 50%. Assays were performed in tripli-
cate.
† 50% cytotoxic concentration, or concentration required to reduce
cell growth by 50%. Assays were performed in triplicate.
§ Martinez et al., 2000b.
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